On Thursday, Shares of AFLAC Incorporated (NYSE:AFL), gained 0.70% to $62.22.
Aflac, released its 2014 Corporate Citizenship Report. The informative online document, accessible at Aflac.com, highlights the accomplishments of the company in the area of citizenship, counting reports on company innovation, diversity and philanthropy in 2014. According to the report, the $23.9 billion dollar company places a premium on ethics and integrity, which they call the “Aflac Way.”
“The Aflac Way, simply put, is our company’s philosophy that encourages our employees at every level to do the right thing regardless of whether anyone is watching,” Aflac Chairman and CEO Dan Amos said. “From our humble startings 60 years ago to recently, a Fortune 500 company, we have always maintained that if you do business with fairness, transparency and ethics, customers will reward you with their business – and they have.”
Aflac Incorporated, through its partner, American Family Life Assurance Company of Columbus, provides supplemental health and life insurance products. It operates through two segments, Aflac Japan and Aflac U.S.
Shares of Yelp Inc (NYSE:YELP), inclined 0.31% to $35.11, during its last trading session.
Blue Calypso, declared a favorable set of Claim Construction or “Markman” rulings from the United States District Court for the Eastern District of Texas in its ongoing patent infringement case against Groupon (GRPN), Foursquare, Yelp (YELP) and IZEA.
On July 14, 2015, the Court entered its Memorandum Opinion and Order regarding claim construction. In that Order, the Court analyzed eleven (11) claim terms. The Court agreed with Blue Calypso’s proffered construction as to seven (7) terms, chose its own construction as to three (3) terms and agreed with Defendants’ proffered construction as to only one (1) term. The Court also expressly rejected Defendants’ argument that the term “testimonial tag” was indefinite.
Yelp Inc. operates a platform that connects people with local businesses in the United States. Its platform covers various local business categories, counting restaurants, shopping, beauty and fitness, arts, entertainment and events, home and local services, health, nightlife, travel and hotel, auto, and others categories.
At the end of Thursday’s trade, Shares of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), lost -4.55% to $2.31.
Actinium Pharmaceuticals, declared that it has presented a request for a pre-IND (Investigative New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company’s Iomab-B drug candidate presently preparing to commence the pivotal Phase 3 trial. During the early development of a new drug, manufacturers are required to apply for and obtain IND designation.
“We are optimistic that we will move through the meeting and application process successfully and obtain approval from the FDA that will allow us to move into the critical Phase 3 phase for Iomab-B,” noted Kaushik J. Dave, President and Chief Executive Officer of Actinium Pharmaceuticals. “We have also begun to establish the infrastructure necessary to enable speedy Phase 3 development of Iomab-B, if and when we receive IND status.”
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies.
Finally, CymaBay Therapeutics Inc (NASDAQ:CBAY), ended its last trade with -0.74% loss, and closed at $2.68.
CymaBay Therapeutics, declared the pricing of its underwritten public offering of 7,120,000 shares of its common stock at a price to the public of $2.81 per share, for predictable gross proceeds of about $20 million. The net proceeds to CymaBay are predictable to be about $18.4 million, after deducting the underwriting discount and estimated offering expenses payable by CymaBay. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 1,068,000 shares from CymaBay at the public offering price. CymaBay anticipates using the net proceeds from the offering for general corporate purposes, counting clinical trials, research and development, capital expenditures and working capital. The offering is predictable to close on July 20, 2015, subject to customary closing conditions.
Piper Jaffray & Co. is acting as the sole book-running manager for the offering, and LifeSci Capital LLC is acting as the lead manager.
CymaBay Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, counting serious rare and orphan disorders. Arhalofenate, the Company’s lead product candidate, is used to treat gout.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
